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OBJECTIVE—The endogenous cannabinoid (or endocannabi-
noid) system (ECS) is part of a central neuromodulatory system
thought to play a key role in the regulation of feeding behavior
and energy balance. However, increasing evidence suggests that
modulation of the ECS may also act to regulate peripheral
mechanisms involved in these processes, including lipogenesis in
adipose tissue and liver, insulin release from pancreatic -cells,
and glucose uptake into skeletal muscle. It was recently shown
that cannabinoid receptor type 1 (CB1) and type 2 (CB2), both
key components of the ECS, are expressed in human and rodent
skeletal muscle. However, their role in modulating insulin sensi-
tivity in this metabolically active tissue has yet to be determined.
Our aim was to establish the role, if any, of these receptors in
modulating insulin sensitivity in skeletal muscle cells.
RESEARCH DESIGN AND METHODS—Cultured skeletal
muscle cells were exposed to CB1 and/or CB2 pharmacological
agonists/antagonists/inverse agonists, and the resulting effects on
insulin-regulated phosphatidylinositol 3 kinase (PI 3-kinase)–
protein kinase B (PKB) and extracellular signal–related kinases
1/2 (ERK1/2)-directed signaling were determined.
RESULTS—Here, we report that modulating the activity of the
ECS in skeletal muscle regulates both insulin-dependent mito-
gen-activated protein (MAP) kinase (ERK1/2) and the canonical
PI 3-kinase/PKB signaling pathways. We show that pharmacolog-
ical activation or inhibition of CB1 receptor activity exerts a
differential effect with regard to MAP kinase– and PKB-directed
signaling.
CONCLUSIONS—Our study provides evidence that signaling
via cannabinoid receptors can signiﬁcantly modulate mitogenic
and metabolic signaling in skeletal muscle with important impli-
cations for muscle growth and differentiation as well as the
regulation of glucose and lipid metabolism. Diabetes 59:375–
385, 2010
T
he increasing occurrence of obesity continues to
pose major health problems globally and is
linked with the growing incidence of conditions
such as type 2 diabetes and cardiovascular dis-
ease (1,2). The mechanisms involved in the pathogenesis
of type 2 diabetes are not yet fully understood and
therefore are the focus of intense study. Insulin resistance
probably develops due to unfavorable alterations in the
insulin signal transduction pathways that are important for
controlling glucose homeostasis in target tissues, such as
liver, adipose tissue, and skeletal muscle (3,4). Initiation of
these pathways stems from the activated insulin receptor
kinase that can bind and regulate numerous downstream
intracellular targets, such as the insulin receptor substrate
(IRS) proteins, phosphatidylinositol 3 kinase (PI 3-kinase),
and growth factor receptor–bound protein 2 (5–7).
The endocannabinoid signaling system (ECS) has been
shown to inﬂuence multiple metabolic pathways, via both
its central and peripheral actions (8–10). Key components
of this system include the 7-transmembrane endocannabi-
noid receptors (cannabinoid [CB] receptors) and endoge-
nous lipid-derived endocannabinoid ligands such as
anandamide and 2-arachidonoylglycerol (2-AG) (9). From
work carried out in neurons, it is widely acknowledged
that these endocannabinoids are not stored in cells but are
produced “on-demand” from lipid precursors in response
to elevated levels of intracellular calcium (11). The mech-
anisms by which endocannabinoids are synthesized in
peripheral tissues have yet to be established.
CB receptors belong to the superfamily of G-protein–
coupled receptors, where the two principle subtypes, type
1 (CB1) and type 2 (CB2), are established as the mediators
of the majority of the biological effects of cannabinoid
ligands. Although these receptors are both Gi/o coupled,
they do display very different pharmacological proﬁles and
patterns of expression (8). The CB1 receptor, in particular,
has been detected in adipose tissue, liver, muscle, and
pancreas and is the most abundantly expressed G-protein–
coupled receptor in the brain (8,12–14). CB2 receptors, on
the other hand, are expressed primarily in spleen and
leukocytes (8,15).
The ECS is known to regulate energy balance and
initially this was thought to occur via its central effects on
feeding behavior, although more recent evidence suggests
it may also regulate lipid and glucose metabolism by direct
actions on peripheral targets (8,9,12). The generation of
genetic mouse knockout models and the discovery of
SR141716, a CB1 selective inverse agonist, have greatly
contributed to our understanding of the role of the ECS in
the regulation of energy metabolism (16,17). Centrally,
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appetite and promote weight loss, effects that are also
seen in mice lacking the CB1 receptor (12,17). On the
other hand, with regard to peripheral effects, SR141716
acts to suppress lipogenesis in both liver and adipose
tissue promoted by endocannabinoids acting via the CB1
receptor (9,18,19). In addition, pharmacological inhibition
of the CB1 receptor increases the expression of adiponec-
tin, an insulin-sensitizing adipokine (20). Overall, longer-
term SR141716 treatment has been shown to reduce
fasting glucose and insulin levels as well as improve lipid
proﬁle in both animals and humans (17,21,22). Emphasiz-
ing these important regulatory roles of CB1 signaling in
metabolism, there is also increasing evidence that the ECS
becomes dysregulated during hyperglycemia and obesity
(9).
Skeletal muscle plays a crucial role in glucose ho-
meostasis by being the primary site of glucose disposal
and fatty acid oxidation, processes that are acutely regu-
lated by insulin (23,24). It is now known that CB1 recep-
tors are expressed in human skeletal muscle (13), and
preliminary evidence suggests that the ECS may have a
role in regulating pathways involved in oxygen consump-
tion and oxidation as well as glucose metabolism (25–27).
However, as yet, little is known with regard to the effects
of manipulating ECS activity on muscle insulin sensitivity.
Here we demonstrate that the CB1 receptor is expressed
in cultured rat skeletal muscle cells in a differentiation-
dependent manner and show for the ﬁrst time that
whereas activating CB1 receptor activity pharmacologi-
cally produces differential effects on the insulin-dependent
regulation of mitogen-activated protein (MAP) kinase (ex-
tracellular signal–related kinases 1/2 [ERK1/2]) and canon-
ical PI 3-kinase/protein kinase B (PKB) signaling, CB1
receptor inverse agonism leads to the insulin sensitization
of both pathways.
RESEARCH DESIGN AND METHODS
Materials. Bovine insulin was purchased from Sigma-Aldrich (Munich, Ger-
many). WIN55,212-2 (R-()-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-
pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone mesylate), AM630
(6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-
methanone), JWH015 (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmeth-
anone), and ACEA (N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide)
were all purchased from Tocris Bioscience (Bristol, U.K.). SR141716 (N-
(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-
3-carboxamide) was a gift from sanoﬁ-aventis (Frankfurt, Germany). All
antibodies were from Cell Signaling Technology (Beverly, MA) unless stated
otherwise. Anti-actin was purchased from Sigma-Aldrich (St. Louis, MO). Both
IRS-1 and p85 (PI 3-kinase) antibodies were from Millipore (Watford, U.K.).
The antibody against the CB1 receptor together with rat CB1 and rat CB2
cDNA were generated by the Mackie laboratory (Indiana University) (28).
Horseradish peroxidase–conjugated anti-(rabbit IgG) and anti-(mouse IgG)
were obtained from New England Biolabs (Beverley, MA).
Cell culture and transient transfection. L6 cells were cultured to myo-
tubes in -minimum essential medium containing 2% (vol/vol) FBS (Life
Technologies, Paisley, U.K.) and 1% (vol/vol) antibiotic/antimycotic solution
(100 units/ml penicillin, 100 g/ml streptomycin, and 250 ng/ml amphotericin
B) at 37°C with 5% CO2. HEK-293AD and HEK-293T cells were maintained in
a humidiﬁed 5% CO2, 37°C incubator in Dulbecco’s modiﬁed Eagle’s medium/
F12 with 10% (vol/vol) FBS. Transient transfections in HEK-293 cells were
carried out using Lipofectamine 2000 (Invitrogen), according to manufactur-
er’s instructions.
Cell lysis and immunoblotting. L6 myotubes were lysed after experimental
treatment in an appropriate volume of lysis buffer (29). Cell lysates (40 g)
were subjected to SDS/PAGE on a 10% resolving gel and immunoblotted as
previously described (29). Immobilon-P membranes (Millipore, Bedford, MA)
were probed with different primary antibodies as described in the ﬁgure
legends. Primary antibody detection was performed with the appropriate
horseradish peroxidase–conjugated anti-rabbit or anti-mouse IgG and result-
ing signals visualized using enhanced chemiluminescence by exposure to
Konica Minolta X-ray autoradiographic ﬁlm.
Immunoprecipitation. L6 myotubes were lysed as described above. IRS-1
was immunoprecipitated overnight at 4°C from 400 g of cell lysate protein
using an anti–IRS-1 antibody. The resulting immunocomplex was conjugated
to protein-G-Sepharose beads and solubilized in Laemmli sample buffer prior
to immunoblotting.
RNA isolation and semiquantitative RT-PCR. Total RNA was extracted
from L6 myoblasts or myotubes using TRI Reagent (Sigma-Aldrich, Dorset,
U.K.) according to the manufacturer’s instructions. The extracted RNA (1
g) was used as the template for cDNA synthesis performed using the
Improm-II Reverse Transcription System (Promega, Madison, WI) accord-
ing to manufacturer’s instructions. Primers used for PCR ampliﬁcation were
from previously published sequences and were as follows: Forward 5-3,
GGCATCTCTTTCTCAGTCAC, reverse 5-3, ATCAGGTAGGTCTCGTCAAT
(30). PCR ampliﬁcation was performed using the following cycling conditions:
94°C for 2 min followed by (for 28 cycles) 94°C for 1 min, 60°C for 1 min, and
72°C for 2 min. Final extension was carried out at 72°C for 5 min. The
ampliﬁcation reaction was carried out using GoTaq Flexi DNA polymerase
according to manufacturer’s instructions (Promega). PCR products were then
analyzed by agarose gel electrophoresis.
Design and cloning of short hairpin RNAs. Short hairpin RNA (shRNA)
sequences were inserted into the pLKO.1-puro lentiviral vector (Sigma-Aldrich, St.
Louis, MO) as follows. Each hairpin consisted of a 21-nucleotide sense sequence,
a short hairpin sequence (CTCGAG), a 21-nucleotide antisense sequence, and
ﬁve thymidines (a stop signal for RNA polymerase). Oligonucleotides (oligos)
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FIG. 1. CB1 expression in myoblasts and myotubes. A: The presence of CB1 mRNA was conﬁrmed by conventional RT-PCR analysis of RNA
isolated from L6 myotubes. B: Expression of CB1 receptor protein was compared in lysates (40 g) obtained from L6 myoblasts and myotubes
by immunoblotting using a CB1 antibody. C: Speciﬁcity of this CB1 antibody was conﬁrmed by immunoblot analysis of lysates isolated from
HEK-293AD cells transfected with or without (CON) wild-type CB1 (HEK-CB1) or CB2 receptor (HEK-CB2).
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loop is indicated by italics): forward CCGGAACAAGTCTCTCTCGTCGT
TCAACTCGAGTTGAACGACGAGAGAGACTTGTTTTTTTG, reverse AATTC
AAAAAAAGAGCACCGTTAAGATCGCGAACTCGAGTTCGCGATCTTAACGGT
GCTCTT. Additional nucleotides were added to the ends of the oligos as
shown, such that annealing of the two complementary oligos resulted in
overhangs consistent with those generated by EcoRI and AgeI. Oligos were
annealed by mixing 2 g of each oligo, heating to 94°C for 10 min, followed by
cooling at a rate 1°C per minute until 21°C is reached. The ﬁnal double-
stranded DNA sequences were then inserted into pLKO.1-puro at the EcoRI
and AgeI sites. Correct insertions of shRNA were conﬁrmed by sequencing.
Lentivirus production and generation of stable CB1 knockdown L6 cell
lines. Recombinant lentiviruses were produced by cotransfecting HEK-293T
cells with the empty pLKO.1-puro vector, pLKO.1-puro/scramble, or pLKO.1-
puro/CB1 plasmids with the envelope vector pCMV-VSVg and the packaging
vector pHR-CMV8.2R at ratios of 3:2:2, respectively, according to mass.
Infectious lentiviral particles were harvested by collecting the cell culture
media 72 h later and ﬁltered through 0.45-m Minisart cellulose-acetate ﬁlters.
Infection of L6 myoblasts was carried out by adding 1 ml crude lentivirus
preparation to L6 myoblasts seeded in 6-cm dishes in the presence of 8 g/ml
polybrene. Medium was replaced with standard growth medium containing 3
g/ml puromycin 24 h after transduction and cells were maintained in this
selective medium until fully selected.
Statistical analysis. All statistical analysis was performed using one-way
ANOVA. Data analysis was performed using GraphPad Prism software and
considered statistically signiﬁcant at P values  0.05.
RESULTS
CB1 receptors are expressed in differentiated L6
skeletal myotubes. CB1 receptor expression was origi-
nally thought to be exclusive to the brain. However, an
increasing number of studies suggest that these receptors
are also expressed in peripheral tissues, including skeletal
muscle (13). However, to date, no speciﬁc function(s) has
been attributed to these cannabinoid receptors, and their
roles in skeletal muscle physiology remain largely un-
known. In an attempt to address this, we initially assessed
expression of the CB1 receptor in L6 rat skeletal muscle
cells. Using RT-PCR and Western blot analysis, respec-
tively, the expression of the CB1 receptor was conﬁrmed in
fully differentiated L6 myotubes at both the mRNA (Fig. 1A)
and protein (Fig. 1B) level. However, CB1 receptor protein
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FIG. 2. Effects of WIN55,212-2 and ACEA incubation upon insulin-stimulated PKB and ERK1/2 activation. L6 myotubes were incubated in the
absence or presence of either the CB1/2 mixed agonist WIN55,212-2 (WIN) or the CB1 selective agonist ACEA (AC) at the concentrations
indicated for either 30 min (A and C)o r2 4h( B and D) including a 2-h serum starvation period prior to insulin stimulation (100 nmol/l for 10
min). Cell lysates were then analyzed by immunoblotting with phospho-PKB (Thr308 and Ser473), PKB, phospho-ERK1/2, and ERK1/2. Each bar
represents mean  SD of three independent experiments. Asterisks indicate statistically signiﬁcant differences versus untreated cells (*P <
0.05).
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view that its expression is differentiation dependent in skel-
etal muscle (31). Speciﬁcity of the CB1 antibody used was
conﬁrmed by immunoblot analysis performed using lysates
obtained from HEK-293AD cells transiently overexpressing
rat CB1 and CB2 receptors (Fig. 1C).
The mixed CB1/CB2-receptor agonist WIN55,212-2
downregulates insulin-stimulated ERK1/2 activity
but not PKB activation in skeletal L6 myotubes.
Treatment of rat skeletal L6 myotubes with 100 nmol/l
insulin for 10 min after short-term (2-h) serum starvation
leads to robust activation of PKB and ERK1/2 (p42/44
MAPK), as measured by the extent of phosphorylation of
PKB at Thr308 and Ser473, and of ERK1/2 at Thr202/
Tyr204 (Fig. 2A). Acute pretreatment (up to 30 min) using
the mixed CB1/CB2 agonist WIN55,212-2 (100 nmol/l) has
no effect on insulin-stimulated ERK1/2 or PKB activation
(Fig. 2A). However, pretreating L6 myotubes with
WIN55,212-2 (100 nmol/l) for 24 h prior to insulin treat-
ment substantially perturbs the activation of ERK but not
that of PKB (Fig. 2B). Therefore, chronic WIN55,212-2
treatment selectively suppresses insulin-induced activa-
tion of the ERK1/2 pathway, but has no effect on PKB
activation. This is in contrast to a previous study carried
out in glioma cells, demonstrating that longer-term (
12 h) treatment with WIN55,212-2 used at a higher concen-
tration (15 mol/l) can downregulate both ERK1/2 and
PKB activity, although this was done in the absence of any
external hormonal stimulus (32). In another study per-
formed in primary human skeletal muscle, acute exposure
with the endogenous CB1 agonist anandamide alone was
found to transiently activate ERK1/2. However we did not
observe this same effect in the L6 myotubes using the
synthetic CB1 agonists WIN55,212-2 and ACEA, but it is
noteworthy that the effects reported by Eckardt et al. (31)
were observed using a high concentration (10 mol/l) of
anandamide, which may potentially modulate a number of
cellular responses independently of its effect on cannabi-
noid receptors.
WIN55,212-2 mediates its inhibitory effects on
ERK1/2 speciﬁcally through the CB1 receptor. To
determine whether the effect of WIN55,212-2 is mediated
through the CB1 and/or CB2 receptors, we tested the CB1
and CB2 selective agonists ACEA and JWH015, respec-
tively. Acute (30 min) treatment with ACEA (10 nmol/l)
had no effect on either ERK1/2 or PKB activation in
response to insulin (Fig. 2C). However, similar to the
application of WIN55,212-2, a 24-h treatment with ACEA
(10 nmol/l) also led to the inhibition of insulin-stimulated
ERK1/2 activity but had no effect on PKB activation (Fig.
2D). In contrast to the effects of WIN55,212-2 and ACEA,
treating L6 myotubes with JWH015 either acutely (100
nmol/l, 30 min) or with various concentrations longer term
(10 nmol/l to 1 mol/l, 24 h) does not alter insulin-
stimulated activation of ERK1/2 or PKB (Fig. 3), suggest-
ing that the inhibitory effect of WIN55,212-2 on ERK1/2
signaling is mediated selectively through the CB1 receptor.
It should be noted that concentrations of JWH015 less than
100 nmol/l have been shown to inhibit cAMP production
and those less than 1 mol/l, to evoke calcium transients
in HEK-293 cells expressing either the human or rat forms
of the CB2 receptor (33,34).
The CB1 receptor inverse agonist SR141716 sensi-
tizes PKB- and ERK1/2-directed signaling in L6 myo-
tubes. SR141716 (rimonabant) is a selective CB1 receptor
inverse agonist (trade name Acomplia) that has been used
to treat obesity (35). Administration of SR141716 causes a
transient reduction in food intake and sustained reduction
in body weight gain as well as decreases hyperinsulinemia
and reduces circulating levels of free fatty acids in diet-
induced obese rodents and in humans (17,22). Predictably,
these effects of SR141716 are not observed in CB1 recep-
tor–deﬁcient mice fed a high-fat diet (17). To our knowl-
edge, the effects of SR141716 on insulin-induced signaling
responses in skeletal muscle have not yet been fully
elucidated. Therefore, we investigated whether exposing
L6 myotubes to SR141716 would abrogate the effects of
CB1 activation on insulin-stimulated PKB and ERK1/2
activation. Our data demonstrate that SR141716 prevents the
loss in ERK1/2 activity in response to both WIN55,212-2 and
ACEA in a concentration-dependent manner, with the effects
of the agonists completely blocked by 100 nmol/l SR141716
(Figs. 4 and 5). In contrast, application of the CB2 selective
antagonist AM630 (100 nmol/l) had no effect on WIN55,212-2
and ACEA-mediated loss in ERK1/2 activity, again implying
that the modulation of ERK1/2 signaling is selectively medi-
ated through the CB1 receptor (Fig. 4A).
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FIG. 3. The CB2 agonist JWH015 does not modulate insulin-stimulated
ERK1/2 and PKB activation. L6 myotubes were incubated in the
absence or presence of the CB2 selective agonist JWH015 (JW) for the
concentrations indicated for either 30 min (A)o r2 4h( B) including a
2-h serum starvation period prior to insulin stimulation (100 nmol/l for
10 min). Cell lysates were then analyzed by immunoblotting with
phospho-PKB (Ser473), PKB, phospho-ERK1/2, and ERK1/2. Each bar
represents mean  SD of three independent experiments. Asterisks
indicate statistically signiﬁcant differences versus untreated cells
(*P < 0.05).
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or ACEA treatment (both 100 nmol/l) for 24 h also leads to
suppression of insulin-induced cAMP-responsive element–
binding protein (CREB) phosphorylation at Ser133, a
downstream target of ERK1/2 as well as activation of MAP
kinase kinase (MEK) 1/2, the immediate upstream kinase
of ERK (Figs. 4 and 5). Again, similarly to the effects on
ERK1/2, the responses on MEK1/2 and CREB phosphory-
lation are abrogated by coapplication of SR141716 in a
concentration-dependent manner. Interestingly, our data
also demonstrate that the level of insulin-mediated activa-
tion of MEK1/2, ERK1/2, and CREB with coapplication of
SR141716 with WIN55,212-2 was higher than that observed
with insulin alone (Fig. 4B). However, this did not appear
to be the case in the presence of ACEA, possibly due to the
higher afﬁnity of this agonist toward the CB1 receptor
thereby possibly competing more effectively with SR141716
with regard to receptor binding.
In addition to the antagonistic effects of SR141716, we
also investigated whether application of SR141716 alone
would modulate insulin sensitivity in L6 myotubes. Inter-
estingly, pretreatment with SR141716 (100 nmol/l) for 24 h
signiﬁcantly enhances both insulin-stimulated PKB and
ERK activity (Fig. 6), with an approximately twofold and
threefold greater stimulation observed, respectively. This
is despite the lack of any effect of pharmacological CB1
activation on insulin-regulated PKB activity. Consistent
with the increased activation of PKB, the insulin-induced
phosphorylation of forkhead transcription factor in rhab-
domyosarcoma-like 1 (FKHRL1)/Foxo3a (Thr32) and gly-
cogen synthase kinase (GSK) 3/ (Ser21/Ser9), two
important downstream targets of PKB, was also further
enhanced after SR141716 pretreatment. It must also be
noted that despite mediating the enhancement of insulin-
stimulated PKB activity, exposure of L6 myotubes to
SR141716 alone does not induce activation of this kinase,
contrary to previously published data (27).
The CB1 receptor inverse agonist SR141716 sensi-
tizes PKB- and ERK1/2-directed signaling in L6 myo-
tubes via the CB1 receptor. To determine whether the
insulin-sensitizing effects of SR141716 are mediated
through the CB1 receptor, we generated stable CB1 knock-
down L6 cells using shRNA expression vectors and con-
ﬁrmed suppression of CB1 expression by 	70% (Fig. 7). As
in normal wild-type L6 cells, those transfected with silenc-
er-negative control small interfering RNA also show en-
hanced PKB and ERK1/2 activation in response to insulin
after SR141716 treatment (Fig. 7). In contrast, genetic
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FIG. 4. The inhibitory effects of WIN55,212-2 on ERK1/2 activity are prevented by the CB1 receptor antagonist SR141716. L6 myotubes were
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min). L6 myotubes were also pretreated with WIN55,212-2 (100 nmol/l) for 24 h in the presence of SR141716 at the different concentrations
indicated. Cell lysates were then analyzed by immunoblotting for phospho-ERK1/2, ERK1/2, phospho-MEK1/2, phospho-CREB, phospho-PKB, and
PKB as indicated (B), with quantiﬁcation of three independent experiments (mean  SD) shown (C). Asterisks indicate statistically signiﬁcant
differences versus untreated cells (*P < 0.05).
C. LIPINA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 379silencing of CB1 leads to a loss in SR141716-mediated
insulin sensitization in L6 cells with respect to the activa-
tion of both ERK1/2 and PKB.
Effects of SR141716 on insulin-induced IRS-1/p85
association and PKB phosphorylation/dephosphory-
lation. Insulin-stimulated activation of PI 3-kinase is de-
pendent largely on the interaction of its regulatory
subunit, p85, with the IRS proteins. Therefore, by immu-
noprecipitation, we assessed whether the interaction be-
tween p85 (PI 3-kinase) and IRS-1 was altered by
modulation of CB1 receptor function. Treatment of L6
myotubes with either the CB1 selective agonist ACEA (10
nmol/l) or the CB1 inverse agonist SR141716 (100 nmol/l)
for 24 h did not alter IRS-1/p85 association either under
basal or insulin-stimulated conditions (Fig. 8A). This is
also consistent with the lack of detectable activation of
PKB when SR141716 is applied alone (Fig. 6), and suggests
that regulation of CB1 receptor function does not by itself
alter PI 3-kinase activity.
Another potential explanation for SR141716-mediated
sensitization of insulin-regulated signaling may involve the
suppression of phosphatase activity toward target kinases.
To explore this possibility, L6 myotubes were treated with
or without SR141716 for 24 h prior to insulin stimulation,
followed by insulin washout for up to 30 min in the
presence of a PI 3-kinase inhibitor, to determine the level
of PKB activity under postinsulin washout conditions. In
contrast to control (vehicle-treated) cells, those incubated
with SR141716 display a signiﬁcantly delayed loss in PKB
phosphorylation at Ser473 during postinsulin washout
(Fig. 8B). This therefore suggests that SR141716 acts
through CB1 to suppress phosphatase activity toward this
site, thereby maintaining PKB in its active state.
DISCUSSION
The endocannabinoid system (ECS) has emerged as a key
regulator of energy balance, and inhibiting CB1 receptor
function is a potential treatment for obesity. Although the
effects of the ECS on metabolism are mediated both
centrally and peripherally, recent studies have shown that
CB1 inverse agonists/antagonists such as SR141716
(Acomplia) do not need to act centrally to improve circu-
lating lipid proﬁle and glucose metabolism in the obese
state (10,36). The clinical implementation of SR141716 as a
counter-obesity drug has, however, been hindered by its
central nervous system side effects, resulting in an unfa-
vorable risk-beneﬁt ratio. Nevertheless, a new generation
of peripherally acting CB1 inverse agonists/antagonists is
currently under clinical development. Identifying skeletal
muscle as a potential site of action for the effects of CB1
antagonists/inverse agonists on metabolic processes sup-
ports the idea that peripheral cannabinoid targets may be
of therapeutic beneﬁt. Indeed, previous studies have dem-
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FIG. 5. The inhibitory effects of ACEA on ERK1/2 activity are prevented by the CB1 receptor antagonist SR141716. L6 myotubes were incubated
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for phospho-ERK1/2, ERK1/2, phospho-MEK1/2, phospho-CREB, phospho-PKB, and PKB as indicated (A), with quantiﬁcation of three indepen-
dent experiments (mean  SD) shown (B). Asterisks indicate statistically signiﬁcant differences versus untreated cells (*P < 0.05).
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agonist SR141716 elevates glucose uptake in soleus mus-
cle isolated from leptin-deﬁcient obese mice as well as in
cultured L6 skeletal muscle cells (25,27). These studies
were the ﬁrst to implicate a role for the CB1 receptor in
skeletal muscle function and suggest that tonic CB1 recep-
tor activity inﬂuences glucose metabolism in this tissue. In
this study, we have manipulated CB receptor function by
pharmacological means in an attempt to evaluate the
importance of the ECS upon insulin action in muscle cells.
Our ﬁndings indicate that modulating CB1 receptor
function by selective agonists/inverse agonists can regu-
late the responsiveness of skeletal muscle toward insulin
through its action on two key signaling pathways, namely
PI 3-kinase/PKB and the Raf-MEK1/2-ERK1/2 phosphory-
lation cascade. This is an important ﬁnding that suggests
that the upregulation of endocannabinoid/CB1 tone, as
observed in obese animal models and humans, may lead to
altered insulin sensitivity in peripheral tissues such as
skeletal muscle. Crucially, endocannabinoid levels have
previously been shown to be elevated in soleus muscle of
mice fed a high-fat diet in accordance with hyperglycemia
(37). This work also raises the likelihood of cross talk
between CB1 receptor function and upstream components
of insulin signaling involved in the regulation of PKB and
ERK1/2.
Our data demonstrate that longer-term pharmacological
activation of the CB1 receptor function leads to the
selective inhibition of ERK1/2-mediated signaling, while
having little or no effect on PKB activity. Furthermore, we
have shown for the ﬁrst time that treatment with the CB1
inverse agonist SR141716 alone can improve insulin sen-
sitivity in skeletal muscle as determined by its ability to
enhance both insulin-stimulated PKB- and ERK1/2-di-
rected signaling. However, although activation and inhibi-
tion of CB1 are consistent with the inhibitory and
stimulatory effects on ERK1/2 activation, respectively, a
discrepancy arises when comparing the effects of CB1
agonism and inverse agonism with regard to modulating
PKB activity.
It remains unclear what accounts for the distinct effects
of CB1 receptor modulation toward PKB- and ERK1/2-
directed signaling, but there are a number of possibilities
that may help explain the basis of this differential control.
It is plausible, for example, that some level of cross-talk
exists between the CB1 receptor and insulin receptor
signaling, resulting in the speciﬁc downregulation of the
Ras/Raf/ERK cascade—for instance, this may be due to
interference with the ability of adapter molecules such as
growth factor receptor–bound protein 2 and Shc to bind to
the insulin receptor, or possibly involving the downregu-
lation in expression or activity of one or more of these
components. Furthermore, this might occur without alter-
ing IRS protein functionality, thereby maintaining PI 3-ki-
nase/PKB signaling capability. Second, CB1 activation may
lead to increased phosphatase activity toward the Ras/Raf/
ERK cascade, resulting in its inhibition, while having little
or no effect toward components of the PI 3-kinase/PKB
pathway.
In contrast to the effects observed with the CB1 ago-
-+-+
SR (100nM, 24h)
- +         - +
SR (100nM, 24h)
-+ -+
SR (100nM, 24h)
-+ - +
SR (100nM, 24h)
-+ -+
SR (100nM, 24h)
Insulin (50 nM)
Insulin
Insulin
Insulin
Insulin
GSK3
FKHRL1 ERK
R
e
l
a
t
i
v
e
 
c
h
a
n
g
e
 
i
n
 
p
h
o
s
p
h
o
 
P
K
B
(
p
P
K
B
/
t
o
t
P
K
B
)
R
e
l
a
t
i
v
e
 
c
h
a
n
g
e
 
i
n
 
p
h
o
s
p
h
o
 
E
R
K
(
p
E
R
K
/
t
o
t
E
R
K
)
R
e
l
a
t
i
v
e
 
c
h
a
n
g
e
 
i
n
 
p
h
o
s
p
h
o
 
F
K
H
R
L
1
(
p
F
K
H
R
L
1
/
t
o
t
P
K
B
)
R
e
l
a
t
i
v
e
 
c
h
a
n
g
e
 
i
n
 
p
h
o
s
p
h
o
 
G
S
K
3
(
p
G
S
K
3
/
t
o
t
P
K
B
)
B
A
*
*
* *
0.1
0.2
0.3
0.5
1.0
1.5
2.0
0.1
0.2
0.3
0.4
0.5
0.6
--+ +
*
0.5
1.0
1.5
2.0
PKB
PKB(T308)
PKB(S473)
ERK1/2202/204
PKB473
PKB
PKB308
FKHRL132
GSK3α/β21/9
ERK1/2
FIG. 6. The CB1 receptor antagonist SR141716 enhances insulin-stimulated ERK1/2 and PKB-associated activity. L6 myotubes were incubated
with the CB1 receptor selective antagonist SR141716 (SR; 100 nmol/l) for 24 h including a 2-h serum starvation period prior to insulin stimulation
(50 nmol/l for 10 min). Cell lysates were then analyzed by immunoblotting with phospho-PKB (Thr308 and Ser473), phospho-ERK1/2,
phospho-GSK3, phospho-FKHRL1, PKB, and ERK1/2 antibodies as indicated (A), with quantiﬁcation of three independent experiments (mean 
SD) shown (B). Asterisks indicate statistically signiﬁcant differences between insulin-stimulated SR141716-treated and untreated cells (*P <
0.05).
C. LIPINA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, FEBRUARY 2010 381nists, applying SR141716 alone potentiated both insulin-
stimulated PKB and ERK1/2 activity. In view of our data
showing that applying SR141716 alone does not activate
PKB to any appreciable extent, we would discount any
additive effect of insulin and SR141716. Instead, our ob-
servations support the notion that SR141716 acts to poten-
tiate insulin-stimulated PKB activity and because this
enhancement in PKB activation is not observed in cells
where CB1 expression has been silenced (Fig. 7), it
implicates a role for the CB1 receptor in this sensitization.
The potentiation of PKB and ERK1/2 activation by
longer-term SR141716 treatment may arise through several
different mechanisms. First, it may be due to an increase in
the expression of the upstream components of insulin
signaling such as the insulin receptor, IRS-1/2, or the
regulatory and catalytic subunits of PI 3-kinase. However,
we do not observe any detectable elevation of PKB or
ERK1/2 activity when SR141716 is applied alone, as mea-
sured by the extent of their phosphorylation as would be
expected in such a scenario. In addition, there is no
observed enhancement in association between IRS-1 and
the p85 regulatory subunit of PI 3-kinase, implying that it
is unlikely that SR141716 is acting via the modulation of PI
3-kinase activity. Nevertheless we cannot rule out the
possibility that a marginal increase in these upstream
components may contribute to the insulin sensitization
(27). Another possible explanation may involve SR141716
“priming” the cell for stimulation by insulin by disrupting
the inhibitory environment acting on PKB and ERK1/2
under basal conditions. For instance, this may involve
relieving the inhibitory action of various phosphatases that
can negatively regulate insulin responses (38–43). We
have observed that SR141716 does not alter expression of
phosphatase and tensin homolog (PTEN) in L6 myotubes
(data not shown), although the possibility that it may
change the expression and/or activity of other important
protein phosphatase(s) such as protein tyrosine phospha-
tase 1B (PTP-1B) or Src homology domain 2 (SH2)-
containing tyrosine phosphatase-1 (SHP-1) cannot be
excluded. Indeed, our data demonstrating that SR141716
delays dephosphorylation of PKB at Ser473 during insulin
washout provide evidence in support of such a mecha-
nism. However, further work will be required to elucidate
the identity of the phosphatase(s) involved. Another ex-
planation may arise from the localization of CB1 receptors
at the plasma membrane. For example, these receptors are
found to be present within caveolae, well-characterized
lipid rafts that perform a number of signaling functions
(44). Caveolae are cholesterol-rich microdomains that act
to retain PKB in a repressed state via the action of atypical
protein kinase Cs (45). Because insulin receptors are also
known to reside within caveolae, it is possible that the
close proximity of the cannabinoid receptors causes them
to be involved in modulating insulin receptor–mediated
signaling. One way to test this idea would be to determine
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a diminished number of caveolae.
Consistent with the inhibition of ERK1/2, WIN55,212-2
or ACEA treatment for 24 h also suppresses insulin-
induced CREB phosphorylation at Ser133, a downstream
target of ERK1/2, as well as the activation of MEK1/2, the
immediate upstream kinase of ERK (Figs. 4 and 5). This
suggests that the effects of CB1 agonism on ERK1/2-
mediated signaling are acting at the level of MEK1/2 or
above, possibly affecting the activity of the GTPase Ras or
the MAPK kinase Raf, both of which lie upstream of
ERK1/2 and MEK1/2 in the signaling cascade. It has also
been demonstrated previously that antagonists/inverse
agonists of the CB1 receptor can lead to an increase in the
levels of cAMP, which in turn promotes activation of
protein kinase A (27,46). Protein kinase A has also been
shown to phosphorylate Raf-1 thereby preventing it from
binding to Ras-GTP through its association with 14-3-3
proteins (47). This would ultimately lead to an inhibition
of the Ras-Raf-ERK signaling cascade. However, in our
case, SR141716 acts to potentiate the activation of ERK by
insulin, thereby implicating a different response that can
override any effects of enhanced cAMP production as
SR141716 has been shown to cause in L6 cells (27).
This work also raises the question as to whether
SR141716 is functioning as an antagonist by inhibiting
constitutive/tonic CB1 activity in the L6 cells or by acting
as an inverse agonist as reported in other cell types
(48,49). Importantly, although complete silencing of CB1
receptor expression using shRNA was not achieved, the
remaining levels of receptor (	30%) are insufﬁcient to
convey the insulin-enhancing effects of SR141716. This
suggests that some threshold level of CB1 receptor expres-
sion is required to be present in order for SR141716 to act
as a positive modulator of insulin signaling. In addition,
because we did not observe enhancement of PKB and/or
ERK1/2 activity in response to insulin in the CB1 knock-
down cells compared with the silencer-negative control
cells (Fig. 7), we propose that CB1 receptor occupancy by
SR141716 is required for mediating these insulin-sensitiz-
ing effects, whereas inhibition through suppression of
receptor expression does not produce the same response.
Therefore, at least in cultured L6 muscle cells, pharma-
cological activation of the CB1 receptor acts to selectively
inhibit ERK1/2, while largely unaffecting PKB and its
associated activity. Intriguingly, blockade of CB1 receptor
function acts to abrogate impedance toward signaling and
enhance both insulin-stimulated ERK1/2 and PKB activity.
In conclusion, our results further contribute to the grow-
ing body of evidence that the ECS does have an important
role in modulating muscle function and, in accordance
with the reported behavioral side effects of SR141716,
support the use of peripheral instead of central CB1
inverse agonism/antagonism to treat obesity and meta-
bolic disorders.
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